<DOC>
	<DOCNO>NCT02733042</DOCNO>
	<brief_summary>This open-label , multicenter , global study design determine recommend phase 2 dose , safety , efficacy , pharmacokinetics/pharmacodynamics durvalumab subject certain lymphoma subtypes CLL . Globally , 253 subject may enrol 4 treatment arm , include durvalumab monotherapy ; durvalumab combination lenalidomide± rituximab ; ibrutinib ; rituximab ± bendamustine . The study 3 part : dose finding , dose confirmation , dose expansion . Subjects receive monotherapy may receive combination therapy involved-field radiation single nodal site time progressive disease .</brief_summary>
	<brief_title>A Study Determine Dose , Safety , Efficacy Durvalumab Monotherapy Combination Therapy Subjects With Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subject histologically confirm document Bcell lymphoma ( eg , follicular , diffuse large Bcell , mantle cell , small lymphocytic , Hodgkin lymphoma ) chronic lymphocytic leukemia . 2 . Subject highrisk chronic lymphocytic leukemia/small lymphocytic lymphoma . 3 . Subject previously treat least one prior systemic chemotherapy , immunotherapy , chemoimmunotherapy . 4 . Subject Eastern Cooperative Oncology Group performance status 0 , 1 , 2 . 5 . Subject willing able undergo biopsy . 6 . Subject document active relapsed refractory disease require therapeutic intervention . 7 . Subject lymphoma measurable disease ( ≥ 2.0 cm long dimension compute tomography ) chronic lymphocytic leukemia need treatment . 8 . Subject fulfills follow laboratory requirement Exclusion Criteria 1 . Subject central nervous system ( CNS ) meningeal involvement lymphoma . 2 . Subject histopathologic finding consistent myelodysplastic syndrome bone marrow study . 3 . Subject receive prior monoclonal antibody PD1 PDL1 and/or prior : 1 . Arm A : ImiDs ( eg , lenalidomide , thalidomide ) ; 2 . Arm B : ibrutinib Bruton 's tyrosine kinase ( BTK ) inhibitor ; 3 . Arms C : bendamustine 4 . Subject active autoimmune disease . 5 . Subject history organ transplant allogeneic hematopoietic stem cell transplantation . 6 . Subject seropositive active viral infection hepatitis B virus ( HBV ) ( hepatitis B surface antigen [ HBsAg ] positive and/or detectable viral DNA ) 7 . Subject know seropositivity active infection human immunodeficiency virus ( HIV ) hepatitis C virus ( HCV ) . 8 . Subject history primary immunodeficiency tuberculosis . 9 . Subject invasive malignancy within 2 year ( 5 year Arm A ) except noninvasive malignancy cervical carcinoma situ , nonmelanomatous carcinoma skin , ductal carcinoma situ breast , incidental histologic find prostate cancer ( T1a T1b use TNM [ tumor , node , metastasis ] clinical staging system ) has/have surgically cure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Anti-PD-L1 Antibody</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Immune Checkpoint</keyword>
	<keyword>Lymphatic Disease</keyword>
	<keyword>B-Cell Malignancies</keyword>
	<keyword>Abscopal Effect</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , Non Hodgkin ,</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell ,</keyword>
	<keyword>Lymphoma , Follicular</keyword>
	<keyword>Lymphoma , Diffuse Large B-Cell</keyword>
	<keyword>Lymphoma , Mantle Cell</keyword>
	<keyword>Lymphoma , Small Lymphocytic</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
</DOC>